Navigation Links
Hamilton Thorne announces third quarter results
Date:11/24/2009

ology companies, fertility clinics, university research centers and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard University, MIT, Yale, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University and Cambridge.

    Neither the exchange nor its regulation services provider (as that term
    is defined in the policies of the exchange) accepts responsibility for
    the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the company with the Canadian securities regulators, which filings are available at www.sedar.com.

    Financial results included below:

                                                              Balance Sheets
                                                      (Unaudited and in US $)

                                                 September 30,   December 31,
                                                     2009           2008
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Assets

    Current assets:
      Cash                                        
'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
2. Vermillion Announces Appointment of John Hamilton to Board of Directors
3. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
4. PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend
5. Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director
6. Inimex Announces Appointment of New CEO
7. Spherix Announces the Closing of $6.3 Million Registered Direct Offering
8. Spherix Announces Results of Annual Shareholders Meeting
9. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
10. Netech Corporation Announces the Release of IPA 2000 -- Infusion Pump Analyzer for Fast and Accurate Testing of All Infusion Pumps
11. iSirona Announces Go-live at University Hospitals in Cleveland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Boston, MA (PRWEB) September 30, 2014 On ... Director James Sherley in anticipation of a session that ... -organized “Predictive Toxicology Summit,” scheduled for February 17-18, 2015 in ... September 15, Pharma IQ asked Dr. Sherley to respond to ... stem cell toxicity, challenges to evaluating stem cell toxicity, and ...
(Date:9/30/2014)... 30, 2014 Back in the 1970’s, many ... feet. per employee, which included space for circulation and file ... Jeff Howell, partner at Nidea Corporate Real Estate / ... “By the year 2000, however, 250 square feet per ... number come down to 175 to 225 square feet, and ...
(Date:9/29/2014)... diagnostics today, with imaging techniques like MRI (magnetic ... (nuclear magnetic resonance) increasing steeply over the last ... and quality still limit these techniques because of ... hyperpolarization, which involves injecting the patient with substances ... distribution and fate of specific molecules in the ...
(Date:9/29/2014)... Research and Markets  has announced the addition of ... End-User , Application - Global Forecast to 2019" ... oligonucleotide synthesis market is expected to reach $1,712.1 million ... a CAGR of 9.8% from 2014 to 2019. The ... of products and services, applications, end users, and geography. ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3
... NORTH VANCOUVER, BC, July 23 /PRNewswire-FirstCall/ - Chromos ... that the,securities commissions or similar regulatory authorities in ... Quebec have revoked the,cease trade orders against the ... are currently no cease trade orders outstanding against ...
... Duska Therapeutics,Inc. (OTC Bulletin Board: DSKA) ("Duska") announced ... of a proposed Phase 3 clinical study for,its ... Drug Administration,s (the,"FDA") Division of Cardiovascular and Renal ... FDA, including a face-to-face,meeting held on April 16, ...
... 23 Tengion Inc., a clinical,stage biotechnology company focused ... it has appointed Mark Stejbach as Vice,President, Marketing and ... marketing, sales, finance, and managed care experience from,both Merck ... very pleased to welcome Mark to the Tengion executive ...
Cached Biology Technology:Chromos Announces Full Revocation of Cease Trade Orders 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 3Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 4Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning 2
(Date:9/30/2014)... Ludwig-Maximilians-Universitaet (LMU) in Munich report that a new ... sensitive to chemotherapeutic drugs. They have also pinpointed ... target for anti-tumor agents. , Researchers led ... Sieber of the Technische Universitt Mnchen have identified ... new weapon in the fight against malignant tumors. ...
(Date:9/30/2014)... Sept. 30, 2014  Spectra Automation, a ... the biotech and power generation industries, announced ... Bioprocess Manager, an easy-to-use and cost-effective data ... bioprocess development laboratories. Most ... and analyzer systems. Accessing and consolidating data ...
(Date:9/29/2014)... called Clostridium ramosum , coupled with a high-fat diet, ... this week in mBio , the online open-access journal ... team from the German Institute of Human Nutrition Potsdam-Rehbruecke in ... C. ramosum gained weight when fed a high-fat diet. ... less obese even when consuming a high-fat diet, and mice ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... Thanks to laws of elementary electrostatics, we can easily ... and therefore predict their movements. Submerge those particles ... the calculation grows more complex. The charged particles, movements ... or otherwise alter the particles, paths. In this environment ...
... Kevlar and other synthetic fabrics: Step aside. If new ... blouses and other garments made from fibers modeled after ... called the hagfish. The study appears in ACS, journal ... supervisor Douglas S. Fudge and colleagues explain that petroleum ...
... Mainz, Germany and the renowned School of Medicine at ... This strategic partnership promises to provide an innovative stimulus ... University Medical Center. The resulting regular exchange will benefit ... "Our aim is to arrive at a better ...
Cached Biology News:Outside a vacuum: Model predicts movement of charged particles in complex media 2Mainz University Medical Center agrees partnership with Yale University 2
... patented technology, the Lone Wolf valve has ... Open proportional valve available on the market. ... repeatable high-speed performance, and ensures maximum accuracy., ... Enhances system control and patient comfort. , ...
... is the smallest electronic pressure controller ... mm. Parker configured this unit specifically for ... markets. Used in carrier gas flow control, ... dispensing, and hydro-dynamic focusing, the OEM-EPC offers ...
... The VSO LF (Low Flow) offers the same ... control for applications where control is critical or ... solenoid-operated valve automates the flow of gas in ... either DC current or pulse width modulation; closed ...
...
Biology Products: